Mary Caffrey

Findings from the ACTION study were presented during Obesity Week.

The authors acknowledge that use of medical codes to record diagnoses is a limitation of the study.

The rule has several proposals that may be attractive to insurers in the area of risk adjustment.

Authors from a working group of the American Diabetes Association and the European Association for the Study of Diabetes made recommendations that could lead to broader use of technology. CGM systems are poised to make advances that could make them more useful to the larger group of patients with type 2 diabetes.

Sponsors of the survey want to draw attention to the mental health aspects of living with condition, which causes the immune system to overreact.

While Congress debates the fate of the Affordable Care Act, healthcare transformation continues, as seen in an update released this week at Horizon Blue Cross Blue Shield of New Jersey.

While Congress debates the fate of the Affordable Care Act, healthcare transformation continues, as seen in an update released this week at Horizon Blue Cross Blue Shield of New Jersey.

Researchers find that the most common explanation for cognitive symptoms that resemble attention-deficit/hyperactivity disorder is substance abuse.

Authors of survey results and a commentary say it's time to focus on recommendations that can bring clinically meaningful change and cost savings.

The authors find that sleep in teens fell after 2009, as smartphone use escalated. Lack of sleep has been linked to insulin resistance.

The FDA commissioner said regulators would keep special watch over 10 manufacturers who are the sole source of key products. If necessary, they will allow products to be imported from overseas.

Nearly half of the increase in the uninsured rate since the end of 2016 took place in the third quarter, according to the poll.

Despite its clinical success the Diabetes Prevention Program has only reached a fraction of those who need it. That could change once Medicare starts paying for the program next year.

The injectible drug is expected to compete with Eli Lilly's Trulicity after a head-to-head trial showed superior results on glycemic control and weight loss.

Cost-sharing reductions help keep down premiums for policies sold on the exchanges under the Affordable Care Act.

Dupilumab's effectiveness is due to the monoclonal antibody's ability to rapidly reduce inflammation.

Authors of an editorial suggest pregnancy serves as an early stress test on the body, and women who develop gestational diabetes should see it as a signal to adopt a healthy lifestyle.

A study that the American Medical Association commissioned last year found that time spent with electronic health records was taking away from time with patients and contributing to clinician burnout.

The findings generated data on 19 specific clinical variables that could help physicians and patients made personalized decisions about diabetes prevention.

Young adults often have trouble managing a chronic condition as they transition from home to college, but ADHD poses special difficulties.

President Donald Trump acted to fulfill one of his earliest campaign promises and said his executive order would increase choices in healthcare for Americans suffering under the "disaster" of Obamacare.

Catalyst for Payment Reform will use 3 states to pilot new metrics to measure how well healthcare transformation is penetrating individual markets.

The biologic dupilumab had a breakthrough designation when it received FDA approval earlier this year.

Researchers have focused on changes in the gut bacteria to figure out who is at risk for a loss of beta cell function.

The editors cited limits on research by CDC and called on physicians to be more proactive in screening for the presence of guns in homes of those at high risk for suicide.

Healthcare experts increasingly recognize that behavioral science will provide the ideas for reducing the $245 billion annual cost of diabetes in the United States.

The US Preventive Services Task Force already has recommendations for screening and intervention for obesity, but they often are not followed.

Scaling behavioral change and reducing diabetes at the population level were major themes of the meeting.

The announcement does not affect LifeScan, which makes blood glucose management tools and apps. Company officials said an exclusivity deal between Medtronic and UnitedHealthcare was among the factors that contributed to the decision.